

ImQuant Begins Development of New Cancer Technology

ImQuant hires ex-Microsoft software development manager as Vice President of Business and Technology Development.

ImQuant gives presentation outlining its core technology at this year's Radiological Society of North America (RSNA) annual meeting.

Boise, ID – December 12, 2005 Imquant, Inc., a biotechnology company based in Boise, is collaborating with the Mayo Clinic (Rochester, MN) to attempt to improve cancer treatment.

ImQuant, Inc., and Mayo have formed a formal collaborative agreement to develop and study ImQuant's initial prototype software. The technology will be created within an imaging laboratory run by Mayo imaging scientist Richard Robb, Ph.D.

The prototype software is designed to capture data from advanced imaging sources (such as PET, SPECT, MRI, and MR Spectroscopy), and before conventional medical images are created, to convert the data to ImQuant's proprietary digital imaging format. Rather than representing the data as images, the prototype software will represent cancerous tumors as mathematical models. ImQuant's founder, Timothy Sawyer, M.D. says, "mathematical representations of treatment-induced tumor changes will then be integrated into a series of software-based processes that may give doctors a better idea of how a tumor is responding to the use of chemotherapy, radiation therapy, and surgery -- and of how to make better treatment-related decisions based on this information. This technology has the potential to result in better outcomes, decreased toxicity, and less expense."

Clinical trials to study the new software are currently being designed at the Mayo Clinic, and by oncologists within the Saint Alphonsus Cancer Care Center in Boise. Initial clinical trials will involve cancers of the prostate, breast, head and neck, brain, and rectum. In the Treasure Valley, trials will be available at Saint Alphonsus' Boise, Caldwell, and Nampa locations. Other medical institutions throughout

the United States are also being approached to conduct clinical trials using Imquant's technology.

ImQuant, Inc. was created by Timothy E. Sawyer, M.D. (Saint Alphonsus Cancer Care Center). However, ImQuant now announces that Mr. Thomas Payne has joined the company, as Vice President of Business and Technology. Mr. Payne has college degrees in computer engineering and engineering-physics. He spent 13 years in software development with the Microsoft Corporation in Redmond, WA, managing software development teams on a wide-range of projects. Mr. Payne will be instrumental in transforming ImQuant's vision from the research and development phase, to a set of viable, FDA-approved, commercial products that can be implemented into clinical practice.

Dr. Sawyer was asked to speak about ImQuant's technology at the world's largest and most prestigious academic radiology meeting -- the annual meeting of the RSNA. He presented on November 30th, in Chicago.

ImQuant is currently raising money in its initial funding round, a Series A Preferred Stock round.

About Imquant, Inc. ImQuant was founded in 2004 in Boise, Idaho. ImQuant is involved in the design and implementation of image quantification and patient management software. ImQuant's core technology treats data created during "imaging" as a series of measurements of tumor physiology and molecular composition, to tailor cancer therapy to individuals, and to objectify treatment and diagnosis-related decision-making. ImQuant hypothesizes that a tumor can serve as its own in vivo assay to guide chemotherapy, radiation therapy, and other cancer-related processes. The assay can be used predictively, but also dynamically – to modify treatment once therapy has already been initiated. ImQuant's approach is experimental. A series of clinical trials – currently being designed – will be necessary before the series of clinical products in development can be implemented for general oncology patients. ImQuant's technology has the potential to improve treatment outcomes, and to reduce treatment toxicity and expense.